Indian Drug Companies Increasingly Active In Global M&A
This article was originally published in PharmAsia News
Executive Summary
Indian drug companies are actively making acquisitions and partnering deals in Europe and the U.S. in order to expand their geographic reach
You may also be interested in...
Indian Companies Ramping Up For Follow-On Biologics
Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY
GSK/Ranbaxy Deal Gives Indian Firm Greater Development Charge
Under expansion of 2003 deal, Indian firm will take targets to proof of concept, gaining milestones, possible royalties.
Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.